Cargando…

Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation

Inflammation is ubiquitous in the body, triggering desirable immune response to defend against dangerous signals or instigating undesirable damage to cells and tissues to cause disease. Nanomedicine holds exciting potential in modulating inflammation. In particular, cell membranes derived from cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Huize, Shao, Dan, Lao, Yeh‐Hsing, Li, Mingqiang, Hu, Hanze, Leong, Kam W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685500/
https://www.ncbi.nlm.nih.gov/pubmed/31406672
http://dx.doi.org/10.1002/advs.201900605
_version_ 1783442414097137664
author Yan, Huize
Shao, Dan
Lao, Yeh‐Hsing
Li, Mingqiang
Hu, Hanze
Leong, Kam W.
author_facet Yan, Huize
Shao, Dan
Lao, Yeh‐Hsing
Li, Mingqiang
Hu, Hanze
Leong, Kam W.
author_sort Yan, Huize
collection PubMed
description Inflammation is ubiquitous in the body, triggering desirable immune response to defend against dangerous signals or instigating undesirable damage to cells and tissues to cause disease. Nanomedicine holds exciting potential in modulating inflammation. In particular, cell membranes derived from cells involved in the inflammatory process may be used to coat nanotherapeutics for effective targeted delivery to inflammatory tissues. Herein, the recent progress of rationally engineering cell membrane‐based nanotherapeutics for inflammation therapy is highlighted, and the challenges and opportunities presented in realizing the full potential of cell‐membrane coating in targeting and manipulating the inflammatory microenvironment are discussed.
format Online
Article
Text
id pubmed-6685500
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-66855002019-08-12 Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation Yan, Huize Shao, Dan Lao, Yeh‐Hsing Li, Mingqiang Hu, Hanze Leong, Kam W. Adv Sci (Weinh) Reviews Inflammation is ubiquitous in the body, triggering desirable immune response to defend against dangerous signals or instigating undesirable damage to cells and tissues to cause disease. Nanomedicine holds exciting potential in modulating inflammation. In particular, cell membranes derived from cells involved in the inflammatory process may be used to coat nanotherapeutics for effective targeted delivery to inflammatory tissues. Herein, the recent progress of rationally engineering cell membrane‐based nanotherapeutics for inflammation therapy is highlighted, and the challenges and opportunities presented in realizing the full potential of cell‐membrane coating in targeting and manipulating the inflammatory microenvironment are discussed. John Wiley and Sons Inc. 2019-05-22 /pmc/articles/PMC6685500/ /pubmed/31406672 http://dx.doi.org/10.1002/advs.201900605 Text en © 2019 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Yan, Huize
Shao, Dan
Lao, Yeh‐Hsing
Li, Mingqiang
Hu, Hanze
Leong, Kam W.
Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation
title Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation
title_full Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation
title_fullStr Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation
title_full_unstemmed Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation
title_short Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation
title_sort engineering cell membrane‐based nanotherapeutics to target inflammation
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685500/
https://www.ncbi.nlm.nih.gov/pubmed/31406672
http://dx.doi.org/10.1002/advs.201900605
work_keys_str_mv AT yanhuize engineeringcellmembranebasednanotherapeuticstotargetinflammation
AT shaodan engineeringcellmembranebasednanotherapeuticstotargetinflammation
AT laoyehhsing engineeringcellmembranebasednanotherapeuticstotargetinflammation
AT limingqiang engineeringcellmembranebasednanotherapeuticstotargetinflammation
AT huhanze engineeringcellmembranebasednanotherapeuticstotargetinflammation
AT leongkamw engineeringcellmembranebasednanotherapeuticstotargetinflammation